{
    "id": 1749,
    "fullName": "APC inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "APC inact mut indicates that this variant results in a loss of function of the Apc protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 324,
        "geneSymbol": "APC",
        "terms": [
            "APC",
            "BTPS2",
            "DESMD",
            "DP2",
            "DP2.5",
            "DP3",
            "GS",
            "PPP1R46"
        ]
    },
    "variant": "inact mut",
    "createDate": "09/17/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1714,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2126,
                "therapyName": "Sulindac",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1927,
                    "pubMedId": 19755659,
                    "title": "Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19755659"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1722,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2084,
                "therapyName": "ICG-001",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1915,
                    "pubMedId": 15314234,
                    "title": "A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15314234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1147,
                    "pubMedId": 19759537,
                    "title": "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19759537"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1729,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2085,
                "therapyName": "StAx-35",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1916,
                    "pubMedId": 23071338,
                    "title": "Inhibition of oncogenic Wnt signaling through direct targeting of \u03b2-catenin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23071338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2991,
                "therapyName": "G007-LK",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3387,
                    "pubMedId": 23539443,
                    "title": "A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23539443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1712,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2125,
                "therapyName": "Celecoxib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1924,
                    "pubMedId": 17909047,
                    "title": "Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17909047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1723,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2089,
                "therapyName": "MF tricyclic",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1954,
                    "pubMedId": 23843721,
                    "title": "Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23843721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1715,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2127,
                "therapyName": "Erlotinib + Ibuprofen",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1924,
                    "pubMedId": 17909047,
                    "title": "Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17909047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3147,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2405,
                "therapyName": "NC043",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2218,
                    "pubMedId": 21321609,
                    "title": "A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/\u03b2-catenin signaling and colon cancer cell tumorigenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21321609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3145,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2400,
                "therapyName": "CCT031374",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3150,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2412,
                "therapyName": "Pyrvinium",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2226,
                    "pubMedId": 20890287,
                    "title": "Small-molecule inhibition of Wnt signaling through activation of casein kinase 1\u03b1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20890287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3152,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2453,
                "therapyName": "iCRT-14",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3647,
                    "pubMedId": 21393571,
                    "title": "An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1020,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 737,
                    "pubMedId": 18768809,
                    "title": "Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18768809"
                },
                {
                    "id": 738,
                    "pubMedId": 20080688,
                    "title": "Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20080688"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1726,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2081,
                "therapyName": "PKF115-584",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1950,
                    "pubMedId": 14749129,
                    "title": "Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14749129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17964,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2397,
                "therapyName": "PKF118-310",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1950,
                    "pubMedId": 14749129,
                    "title": "Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14749129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2398,
                "therapyName": "CCT036477",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3161,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 3072,
                "therapyName": "Niclosamide",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3654,
                    "pubMedId": 21531761,
                    "title": "Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21531761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2399,
                "therapyName": "CCT070535",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1685,
                "therapyName": "Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 740,
                    "pubMedId": 22399804,
                    "title": "The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22399804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3140,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2083,
                "therapyName": "FH535",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1914,
                    "pubMedId": 18347139,
                    "title": "A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18347139"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1713,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2124,
                "therapyName": "Celecoxib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1924,
                    "pubMedId": 17909047,
                    "title": "Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17909047"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3146,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2404,
                "therapyName": "iCRT-3",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3647,
                    "pubMedId": 21393571,
                    "title": "An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3149,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2411,
                "therapyName": "JW55",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2223,
                    "pubMedId": 22440753,
                    "title": "A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22440753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17963,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 745,
                    "pubMedId": 20811697,
                    "title": "Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20811697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9085,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 4896,
                "therapyName": "TASIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6906,
                    "pubMedId": 27798265,
                    "title": "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27798265"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1717,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2082,
                "therapyName": "CGP049090",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1950,
                    "pubMedId": 14749129,
                    "title": "Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14749129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3151,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 2452,
                "therapyName": "iCRT-5",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3647,
                    "pubMedId": 21393571,
                    "title": "An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1716,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1949,
                    "pubMedId": 20473900,
                    "title": "Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20473900"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9189,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9192,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9199,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",
            "molecularProfile": {
                "id": 26770,
                "profileName": "APC inact mut PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9193,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9194,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1734,
            "profileName": "APC inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 6502,
                    "name": "CTNNB1 Inhibitor",
                    "profileName": "APC inact mut"
                },
                {
                    "id": 6503,
                    "name": "Tankyrase Inhibitor",
                    "profileName": "APC inact mut"
                }
            ]
        },
        {
            "id": 26770,
            "profileName": "APC inact mut PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26771,
            "profileName": "APC inact mut KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26772,
            "profileName": "APC inact mut KRAS G12D PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}